Brief: Clearmind Medicine Advances Cmnd-100 To Dosing Phase At Hadassah Medical Center
02/12/2025 13:57
Dec 2 (Reuters) - Clearmind Medicine Inc CMND.O: CLEARMIND MEDICINE ADVANCES CMND-100 TO DOSING PHASE AT HADASSAH MEDICAL CENTER IN ONGOING PHASE I/IIA CLINICAL TRIAL FOR ALCOHOL USE DISORDER Source text: ID:nGNX7PJhZk Further company coverage: CMND.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clearmind Medicine
See all newsBrief: Clearmind Advances Dialogue With U.S. Federal Government On Psychedelic Therapies, Submitting Recommendations To FDA
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM